Lack of long-term longitudinal studies studying safety and treatment effect of GLP1RA and SGLT2 inhibitors is a contributing factor to reluctance by regulatory authorities in adapting them as recommended treatment for NAFLD and allograft steatosis. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.